In The Media

May 21, 2018: A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD | OSLI Retina
Read More…

August 14, 2017: ICON-1 Plus Ranibizumab Shows Promise for Wet AMD | MD Magazine.
Read More…